|
Asp
|
asp
|
ASP-YL9 peptide (89YLYNSLLQL97) induces release of IL-2, IFN-gamma, TNF-alpha, or MIP-1beta in antigen-specific CD8+ T-cells |
PubMed
|
|
Envelope surface glycoprotein gp120
|
env
|
HIV-1 gp120-treated myeloid dendritic cell (mDC) downregulates IL-2 and IFN-gamma production compared to LPS-treated mDC |
PubMed
|
|
env
|
HIV-1 gp120 upregulates IL2 secretion in TZM-bl cells |
PubMed
|
|
env
|
HIV-1 gp120 exerts a dose-dependent reduction of IL-2 mRNA expression, IL-2 production, and surface IL-2 receptor expression in CD4+ lymphocytes |
PubMed
|
|
env
|
HIV-1 gp120-specific cell mediated cytotoxicity (CMC) is enhanced by IL-2 or the combination of IL-2 and IFN-alpha |
PubMed
|
|
env
|
Secretion of IL-2 and IFN-gamma stimulated with anti-CD3 antibodies is inhibited by HIV-1 gp120 in T cell lines |
PubMed
|
|
env
|
Binding of HIV-1 gp120 to CD4 downregulates Bcl-2 protein in CD4+ T lymphocytes and facilitates Fas/Fas-ligand triggered apoptosis; addition of IL-2 rescues CD4+ T cells from CD4/gp120-induced Bcl-2 down modulation and apoptosis induction |
PubMed
|
|
env
|
CCR5- and CXCR4-tropic HIV-1 gp120 proteins suppress the ability of NK cells to proliferate in the presence of IL-2 |
PubMed
|
|
env
|
IL-2-induced activation of JAK/STAT5 in human CD4+ T cells is inhibited by HIV-1 gp120 and anti-CD4 antibodies |
PubMed
|
|
env
|
In the presence of HIV-1 gp120, stimulation through the CD28 pathway partially restores IL-2 and IFN-gamma production by T cell lines in response to anti-CD3 antibodies |
PubMed
|
|
env
|
Proliferative responses of lymphocytes to cytomegalovirus are inhibited by relatively high concentrations (greater than or equal to 10 micrograms/ml) of recombinant HIV-1 envelope glycoprotein and this immunosuppression is completely overcome by IL2 |
PubMed
|
|
env
|
HIV-1 gp120 and anti-CD4 antibodies induce a specific, significant decrease in the binding activity of NF-AT, NF-kappa B and AP-1, which leads to an inhibition of IL-2 production and cell proliferation |
PubMed
|
|
env
|
Molecular interactions of CD2 with LFA-3 and CD28 with B7-1 in conjunction with TCR occupancy prevent T cells from programmed apoptosis mediated by binding of CD4 to HIV-1 gp120, resulting in increased levels of IL-2 and IL-4 secretion from the T cells |
PubMed
|
|
Envelope surface glycoprotein gp160, precursor
|
env
|
Pretreatment of CD4+ cells with HIV-1 gp160 significantly reduces PHA-induced secretion of IFN-gamma and IL-2 but augments IL-4 production |
PubMed
|
|
Envelope transmembrane glycoprotein gp41
|
env
|
HIV-1 gp41 or gp120 synthetic peptides induce the production of interleukin (IL)-1 and tumor necrosis factor (TNF); in contrast, gp41 or gp120 synthetic peptides are able to depress the production of interferon (IFN)-alpha, IFN-gamma, and IL-2 |
PubMed
|
|
env
|
An HIV-1 gp41 peptide (amino acid residues 581-597) inhibits both protein kinase C (PKC)-dependent interleukin 2 (IL 2) production and the [Ca2+]i influx-dependent but PKC-independent induction of IL 2 receptor expression |
PubMed
|
|
Nef
|
nef
|
HIV-1 Nef-mediated CTLA-4 downregulation is associated with upregulation of IL-2 production in infected primary CD4+ T-cells |
PubMed
|
|
nef
|
HIV-1 Nef upregulates IL2 secretion when Jurkat cells are stimulated with both CD3 and CD28 |
PubMed
|
|
nef
|
Primary quiescent CD4+ T lymphocytes release both TNF-alpha and IL-2 in response to the treatment with exosomes from cells infected by HIV-1, but not by delta-Nef HIV-1 or Nef (62EEEE/AAAA65) HIV-1 strains |
PubMed
|
|
nef
|
HIV-1 Nef induces the production of IL-2 and interferon-gamma in human T cells |
PubMed
|
|
nef
|
HIV-1 Nef increases IL-2 secretion when Jurkat and primary human CD4 T cells are stimulated through the T cell receptor and the co-stimulus receptor (CD28); this effect depends on Nef myristoylation |
PubMed
|
|
nef
|
HIV-1 Nef inhibits the induction of interleukin 2-directed gene expression |
PubMed
|
|
nef
|
The overall level of IL2 secretion in HIV-1/SIV chimeric Nef expressing cells is higher than that in HIV-1 Nef expressing cells, suggesting that the N-terminal half of Nef harbors molecular determinants that are responsible for T-cell activation |
PubMed
|
|
nef
|
The upregulation of IL2 is impaired by HIV-1 Nef in sub-optimally activated/resting T cells |
PubMed
|
|
nef
|
HIV-1 Nef can facilitate HIV-1 replication in human lymphoid tissue ex vivo by increasing the numbers of productively infected cells and by increasing the responsiveness to IL-2 stimulation |
PubMed
|
|
nef
|
Upon TcR triggering with antigens, HIV-1 Nef specifically downregulates IL-2 and interferon-gamma production in human T cells |
PubMed
|
|
nef
|
HIV-1 Nef suppresses the IL-2-dependent proliferation of CD4+ cells; this suppression is due to the enhanced production of several lymphokines, including interferon-gamma |
PubMed
|
|
Tat
|
tat
|
HIV-1 Tat upregulates IL-2 and IFN-gamma production in stimulated CD8+ T cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates IL-2 expression in activated T-cells and Jurkat T-cells through activation of the IL-2 promoter, an effect involving NF-kappa B, NFAT, and cyclic nucleoside phosphodiesterase 4 |
PubMed
|
|
tat
|
Four mutations (C27S, K51T, R55L, and G79A) on HIV-1 Tat result in the loss of the deleterious effects of Tat on the expression of MHC I, IL-2, and CD25 genes compared with wild-type Tat in Jurkat cells |
PubMed
|
|
tat
|
HIV-1 Tat downregulates IL-2 expression in Jurkat T-cells stably transfected with Tat, H9 T-cells, as well as other T-cells, through an effect on the rel/AP1 complex and IL-2 promoter, resulting in functional unresponsiveness in T-cells |
PubMed
|
|
tat
|
Treatment of T lymphocytes with IL-2, IL-6 and TNFalpha increases CDK9 and cyclin T1 protein levels, suggesting a mechanism for activation of HIV-1 Tat function and reactivation of HIV-1 in CD4+ T lymphocytes harboring a latent provirus |
PubMed
|
|
tat
|
HIV-1 Tat downregulates IL-2 expression in T-cells by inhibiting CD26 which interferes with the delivery or amplification of a signal necessary for IL-2 production |
PubMed
|
|
Vpr
|
vpr
|
HIV-1 Vpr upregulates the gene expression of IL-2 in human monocyte-derived dendritic cells |
PubMed
|
|
vpr
|
HIV-1 Vpr suppresses expression of IL-2 through suppression of NF-kappa B activity via the induction of I kappa B alpha |
PubMed
|
|
capsid
|
gag
|
PLA-p24- or p24-loaded human monocyte-derived dendritic cells enhance HIV-1-specific T-cell response by increased levels of IFN-gamma and IL-2 in comparison with PLA-loaded cells alone |
PubMed
|
|
gag
|
Levels of p24 are significantly higher in cell cultures from HIV-1-exposed infants compared to healthy controls after immune activation by IL-2 or GM-CSF |
PubMed
|
|
gag
|
Unactivated memory CD4+ T cells infected by HIV-1 in the presence of IL-2 and IL-15 alone or IL-6/IL-7/TNF-alpha combination, upregulate granzyme B and HIV-1 CA production |
PubMed
|
|
gag
|
IL-2 enhances HIV-1 p24 Gag expression in STAT5delta silenced CD8-depleted PBMCs of HIV-positive individuals |
PubMed
|
|
gag
|
IFN-gamma and/or IL-2 responses characterized by secreting cells contribute more to the HIV-1 CA specific response in acute infection early disease (AIED) than in chronically infected individuals |
PubMed
|
|
integrase
|
gag-pol
|
Treatment of resting CD4+ T cells with cytokines IL-2, IL-4, IL-7, or IL15 enhances HIV-1 IN mutant D116N to generate de novo virus production |
PubMed
|
|
matrix
|
gag
|
HIV-1 matrix protein colocalizes with syndecan-2, syndecan-4, and CD44v3 on activated CD4+ T cells to modulate TNF-alpha and IL2 production |
PubMed
|
|
gag
|
IL-2-induced down modulation of CD28 is completely prevented by p17 MA, and cells derived from p17-stimulated cultures show a strong Tc1 polarization |
PubMed
|
|
gag
|
HIV-1 Matrix upregulates levels of IL-2, IL-12 and IL-15 in natural killer cells and induces natural killer cell proliferation |
PubMed
|
|
gag
|
HIV-1 Matrix enhances lymphocyte proliferation and IL-2 induced production of interferon gamma and TNF-alpha |
PubMed
|